新型抗癫痫药物奥卡西平基因多态性研究进展  

Research Progress of Gene Polymorphism on Novel Antiepileptic Drug:Oxcarbazepine

作　　者：姚囡囡 田婷婷 黄珊 黄爱文 YAO Nannan;TIAN Tingting;HUANG Shan;HUANG Aiwen(Department of Clinical Pharmacy,The 900th Hospital of Joint Logistics Support Force,Fuzhou 350025,China)

机构地区：[1]中国人民解放军联勤保障部队第九〇〇医院临床药学科,福州350025

出　　处：《中国现代应用药学》2022年第6期856-860,共5页Chinese Journal of Modern Applied Pharmacy

基　　金：中国人民解放军联勤保障部队第九〇〇医院院内课题(2019L16)。

摘　　要：奥卡西平是癫痫部分性发作和全面强直阵挛性发作的首选药物之一,是卡马西平的一种10-酮类衍生物,其耐受性好且不良反应少。然而,临床研究表明奥卡西平在相同群体的不同个体和不同群体之间呈现出显著差异,其中遗传因素起到重要作用。本文通过收集近年来国内外有关奥卡西平代谢酶、转运体、药效靶蛋白以及不良反应方面有关基因多态性的文献报道,进一步明确其对奥卡西平血药浓度、疗效及不良反应的影响,为临床个体化治疗提供参考。Oxcarbazepine is one of the highest priority drugs for partial seizures and general tonic-clonic seizures,it is a 10-ketone derivative of carbamazepine,which is well tolerated and has few adverse reactions.However,clinical studies have shown that oxcarbazepine presents significant differences between different individuals in the same group and different groups,and genetic factors play an important role.This paper collects literature reports on oxcarbazepine metabolic enzymes,transporters,drug-effective target proteins and adverse reactions related to gene polymorphisms at home and abroad in recent years.In addition,this paper further clarified the influence of gene polymorphisms on oxcarbazepine plasma concentration,efficacy and adverse reactions to provide a reference for clinical individualized treatment.

关 键 词：奥卡西平 癫痫 药物基因多态性 

分 类 号：R969.1[医药卫生—药理学]